curative resection

治愈性切除
  • 文章类型: Journal Article
    已显示肿瘤形态(肿瘤负荷评分(TBS))和肝功能(白蛋白与碱性磷酸酶比率(AAPR))与肝内胆管癌(ICC)的预后相关。本研究旨在评估TBS和AAPR对ICC患者生存结局的联合预测作用。我们使用2011年至2018年接受治愈性手术的ICC患者的多中心数据库进行了回顾性分析。采用Kaplan-Meier方法检查新指标(结合TBS和AAPR)与长期结果之间的关系。将该指标的预测效果与其他常规指标进行比较。共有560名患者被纳入研究。基于TBS和AAPR分层,患者分为三组.Kaplan-Meier曲线显示124例TBS低、AAPR高的患者总生存期(OS)和无复发生存期(RFS)最好。而170例高TBS和低AAPR患者的结局最差(log-rankp<0.001)。多变量分析确定组合指数是OS和RFS的独立预测因子。此外,与其他常规指标相比,该指数在预测OS和RFS方面显示出较高的准确性。总的来说,这项研究表明,肝功能和肿瘤形态学的组合在评估ICC患者的预后方面具有协同作用。结合TBS和AAPR的新指标可有效地对接受根治性切除术的ICC患者的术后生存结果进行分层。
    Tumour morphology (tumour burden score (TBS)) and liver function (albumin-to-alkaline phosphatase ratio (AAPR)) have been shown to correlate with outcomes in intrahepatic cholangiocarcinoma (ICC). This study aimed to evaluate the combined predictive effect of TBS and AAPR on survival outcomes in ICC patients. We conducted a retrospective analysis using a multicentre database of ICC patients who underwent curative surgery from 2011 to 2018. The Kaplan-Meier method was employed to examine the relationship between a new index (combining TBS and AAPR) and long-term outcomes. The predictive efficacy of this index was compared to other conventional indicators. A total of 560 patients were included in the study. Based on TBS and AAPR stratification, patients were classified into three groups. Kaplan-Meier curves demonstrated that 124 patients with low TBS and high AAPR had the best overall survival (OS) and recurrence-free survival (RFS), while 170 patients with high TBS and low AAPR had the worst outcomes (log-rank p < 0.001). Multivariate analyses identified the combined index as an independent predictor of OS and RFS. Furthermore, the index showed superior accuracy in predicting OS and RFS compared to other conventional indicators. Collectively, this study demonstrated that the combination of liver function and tumour morphology provides a synergistic effect in evaluating the prognosis of ICC patients. The novel index combining TBS and AAPR effectively stratified postoperative survival outcomes in ICC patients undergoing curative resection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:本研究的目的是研究接受根治性切除术的肝门部胆管癌(pCCA)患者术前体重指数(BMI)与手术感染之间的关系。方法:2008年至2022年连续纳入四家三级医院的pCCA患者。根据术前BMI,患者分为三组:低BMI(≤18.4kg/m2),正常BMI(18.5-24.9kg/m2),BMI高(≥25.0kg/m2)。比较3组患者手术感染的发生率。采用多因素logistic回归模型确定与手术感染相关的独立危险因素。结果:共纳入371例患者,其中BMI正常组283例(76.3%),低BMI组30例(8.1%),高BMI组58例(15.6%)。低BMI和高BMI组的患者手术感染发生率明显高于正常BMI组。多因素logistic回归模型显示,低BMI和高BMI与手术感染的发生具有独立的相关性。结论:与BMI异常的pCCA患者相比,接受根治性切除治疗的BMI正常的pCCA患者可能具有更低的手术感染风险。
    Background: The objective of this study was to investigate the association between pre-operative body mass index (BMI) and surgical infection in perihilar cholangiocarcinoma (pCCA) patients treated with curative resection. Methods: Consecutive pCCA patients were enrolled from four tertiary hospitals between 2008 and 2022. According to pre-operative BMI, the patients were divided into three groups: low BMI (≤18.4 kg/m2), normal BMI (18.5-24.9 kg/m2), and high BMI (≥25.0 kg/m2). The incidence of surgical infection among the three groups was compared. Multivariable logistic regression models were used to determine the independent risk factors associated with surgical infection. Results: A total of 371 patients were enrolled, including 283 patients (76.3%) in the normal BMI group, 30 patients (8.1%) in the low BMI group, and 58 patients (15.6%) in the high BMI group. The incidence of surgical infection was significantly higher in the patients in the low BMI and high BMI groups than in the normal BMI group. The multivariable logistic regression model showed that low BMI and high BMI were independently associated with the occurrence of surgical infection. Conclusions: The pCCA patients with a normal BMI treated with curative resection could have a lower risk of surgical infection than pCCA patients with an abnormal BMI.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:内镜粘膜下剥离术(ESD)是一种技术上具有挑战性的切除技术,用于整块切除发育不良和早期癌性胃肠道(GI)病变。我们进行了一项单臂回顾性研究,评估了在6个美国学术中心进行的用于上下ESD手术的新型可穿针注射电外科刀的安全性和有效性。
    方法:回顾性收集使用新型ESD刀的连续病例资料。主要疗效终点是成功的ESD(整块切除,切缘阴性)。次要疗效终点包括整块切除率,治愈性切除率,ESD时间中位数,和中位数解剖速度。安全性终点是设备或程序相关的严重不良事件(SAE)。
    结果:评估了579例患者的581个病灶的ESD,包括187例(32.2%)上消化道和394例(67.8%)下消化道病变。在283例(48.9%)患者中报告了先前的治疗。成功的ESD在477个(581个中的82.1%)病变中实现,与没有粘膜下纤维化的患者相比,较低(73.6%对87.0%,分别,P<0.001),但与没有以前治疗的患者相似(81.7%对82.3%,分别,P=0.848)。443个(581个中的76.2%)病变符合根治性切除标准。ESD时间的中值为1.0(范围0.1-4.5)小时。平均解剖速度为17.1(IQR5.3-29.8)cm2/小时。15例(2.6%)患者报告了相关的SAE,包括延迟出血(1.9%),穿孔(0.5%),或息肉切除术后综合征(0.2%)。
    结论:一种新开发的可穿针注射的ESD刀在美国中心显示出良好的成功率和良好的安全性。(ClinicalTrials.gov编号,NCT04580940)。
    OBJECTIVE: Endoscopic submucosal dissection (ESD) is a technically challenging resection technique for en-bloc removal of dysplastic and early cancerous gastrointestinal (GI) lesions. We conducted a single-arm retrospective study evaluating the safety and efficacy of a new through-the-needle injection-capable electrosurgical knife used in upper and lower ESD procedures performed at 6 US academic centers.
    METHODS: Data were retrospectively collected on consecutive cases in which the new ESD knife was used. The primary efficacy endpoint was successful ESD (en bloc resection with negative margins). Secondary efficacy endpoints included en-bloc resection rate, curative resection rate, median ESD time, and median dissection speed. The safety endpoint was device- or procedure-related serious adverse events (SAEs).
    RESULTS: ESD of 581 lesions in 579 patients were reviewed, including 187 (32.2%) upper GI and 394 (67.8%) lower GI lesions. Prior treatment was reported in 283 (48.9%) patients. Successful ESD was achieved in 477 (82.1% of 581) lesions ‒ lower for patients with versus without submucosal fibrosis (73.6% versus 87.0%, respectively, P < 0.001), but similar for those with versus without previous treatment (81.7% versus 82.3%, respectively, P = 0.848). Four hundred and forty-three (76.2% of 581) lesions met criteria for curative resection. Median ESD time was 1.0 (range 0.1-4.5) hour. Median dissection speed was 17.1 (IQR 5.3-29.8) cm2/hour. Related SAEs were reported in 15 (2.6%) patients, including delayed hemorrhage (1.9%), perforation (0.5%), or postpolypectomy syndrome (0.2%).
    CONCLUSIONS: A newly developed through-the-needle injection-capable ESD knife showed a good success rate and excellent safety at US centers. (ClinicalTrials.gov number, NCT04580940).
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    目的:本研究的目的是确定与肝细胞癌(HCC)肝切除术(HR)后90天死亡率相关的预测危险因素。
    方法:纳入所有接受单机构和前瞻性维护数据库的HCC择期切除术的患者。进行多因素回归分析以确定择期HR后90天死亡率的术前和术中以及组织病理学预测因素。
    结果:在2004年8月至2021年10月期间,共纳入196例患者(男性148例/女性48例)。研究队列的中位年龄为68.5岁(范围19-84岁)。肝切除(≥3段)率为43.88%。多因素分析显示患者年龄≥70岁[HR2.798;(95%CI1.263-6.198);p=0.011],术前慢性肾功能不全[HR3.673;(95%CI1.598-8.443);p=0.002],Child-Pugh评分[HR2.240;(95%CI1.188-4.224);p=0.013],V期[HR2.420;(95%CI1.187-4.936);p=0.015],切除节段≥3[HR4.700;(95%1.926-11.467);p=0.001]是90天死亡率的主要显著决定因素。
    结论:高龄患者,预先存在的慢性肾功能不全,Child-Pugh评分,扩大肝切除术,和血管肿瘤受累被确定为90天死亡率的重要预测因素。正确选择患者和调整治疗策略可能会降低短期死亡率。
    OBJECTIVE: The aim of this study was to identify predictive risk factors associated with 90-day mortality after hepatic resection (HR) in hepatocellular carcinoma (HCC).
    METHODS: All patients undergoing elective resection for HCC from a single- institutional and prospectively maintained database were included. Multivariate regression analysis was conducted to identify pre- and intraoperative as well as histopathological predictive factors of 90-day mortality after elective HR.
    RESULTS: Between August 2004 and October 2021, 196 patients were enrolled (148 male /48 female). The median age of the study cohort was 68.5 years (range19-84 years). The rate of major hepatectomy (≥ 3 segments) was 43.88%. Multivariate analysis revealed patient age ≥ 70 years [HR 2.798; (95% CI 1.263-6.198); p = 0.011], preoperative chronic renal insufficiency [HR 3.673; (95% CI 1.598-8.443); p = 0.002], Child-Pugh Score [HR 2.240; (95% CI 1.188-4.224); p = 0.013], V-Stage [HR 2.420; (95% CI 1.187-4.936); p = 0.015], and resected segments ≥ 3 [HR 4.700; (95% 1.926-11.467); p = 0.001] as the major significant determinants of the 90-day mortality.
    CONCLUSIONS: Advanced patient age, pre-existing chronic renal insufficiency, Child-Pugh Score, extended hepatic resection, and vascular tumor involvement were identified as significant predictive factors of 90-day mortality. Proper patient selection and adjustment of treatment strategies could potentially reduce short-term mortality.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:肝细胞癌(HCC)根治性切除后的高肿瘤复发率和低生存率仍然值得关注。主要目标是评估与无病相关的预测因素(DFS)和总生存(OS)在肝癌患者的一个子集进行肝切除(HR)。
    方法:在08/2004-7/2021之间,在我们机构的188例患者中进行了HCC的HR。数据分配是从前瞻性维护的数据库中进行的。临床病理因素对DFS和OS的预后影响通过单-和多变量Cox回归分析进行评估。用KaplanMeier方法产生存活曲线。
    结果:术后1-,3年和5年总体DFS和OS率为77.9%,49.7%,41%和72.7%,54.7%,38.8%,分别。肿瘤直径≥45mm[HR1.725;(95%CI1.091-2.727);p=0.020],腹内脓肿[HR3.812;(95%CI1.859-7.815);p<0.0001],和术前慢性酒精滥用[HR1.831;(95%CI1.102-3.042);p=0.020]是糖尿病患者DFS的独立预测因素[HR1.714;(95%CI1.147-2.561);p=0.009),M阶段[HR2.656;(95%CI1.034-6.826);p=0.042],V期[HR1.946;(95%CI1.299-2.915);p=0.001,脓毒症[HR10.999;(95%CI5.167-23.412);p<0.0001],和ISGLSB/C[HR2.008;(95%CI1.273-3.168);p=0.003]是OS的显著决定因素。
    结论:尽管术后复发率高,治愈性HR后,患者的长期生存率可以达到可接受的水平.OS和DFS相关参数的识别改进了以患者为中心的治疗和监测策略。
    BACKGROUND: High tumor recurrence and dismal survival rates after curative intended resection for hepatocellular carcinoma (HCC) are still concerning. The primary goal was to assess predictive factors associated with disease-free (DFS) and overall survival (OS) in a subset of patients with HCC undergoing hepatic resection (HR).
    METHODS: Between 08/2004-7/2021, HR for HCC was performed in 188 patients at our institution. Data allocation was conducted from a prospectively maintained database. The prognostic impact of clinico-pathological factors on DFS and OS was assessed by using uni- and multivariate Cox regression analyses. Survival curves were generated with the Kaplan Meier method.
    RESULTS: The postoperative 1-, 3- and 5- year overall DFS and OS rates were 77.9%, 49.7%, 41% and 72.7%, 54.7%, 38.8%, respectively. Tumor diameter ≥ 45 mm [HR 1.725; (95% CI 1.091-2.727); p = 0.020], intra-abdominal abscess [HR 3.812; (95% CI 1.859-7.815); p < 0.0001], and preoperative chronic alcohol abuse [HR 1.831; (95% CI 1.102-3.042); p = 0.020] were independently predictive for DFS while diabetes mellitus [HR 1.714; (95% CI 1.147-2.561); p = 0.009), M-Stage [HR 2.656; (95% CI 1.034-6.826); p = 0.042], V-Stage [HR 1.946; (95% CI 1.299-2.915); p = 0.001, Sepsis [HR 10.999; (95% CI 5.167-23.412); p < 0.0001], and ISGLS B/C [HR 2.008; (95% CI 1.273-3.168); p = 0.003] were significant determinants of OS.
    CONCLUSIONS: Despite high postoperative recurrence rates, an acceptable long-term survival in patients after curative HR could be achieved. The Identification of parameters related to OS and DFS improves patient-centered treatment and surveillance strategies.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    胆管癌(CLC)是一种极为罕见的肿瘤,被归类为小导管型肝内胆管癌(iCCA)的亚型。关于CLC的详细报道很少,肿瘤异质性对预后的影响尚不清楚。2006年4月至2022年6月,在金泽大学医院就诊的774例原发性肝癌切除病例中,通过对其分子和生物学特征的免疫组织化学分析,14例经病理诊断为CLC。回顾性评估临床病理特征和预后。此外,评估了肿瘤异质性,并根据单个肿瘤中CLC组分的比例将肿瘤分为纯类型和部分类型.在9例患者中观察到慢性肝病(64.3%)。所有肿瘤都是肿块形成的,病理R0切除11例(78.6%)。肿瘤异质性在11例(78.6%)患者中被分类为单纯的,在3例(21.4%)患者中被分类为部分的。中位随访时间为59.5个月(12~114个月)。单纯和部分患者的5年疾病特异性生存率没有差异(90.0%vs.100.0%;P=0.200)类型,但R0切除组的比率明显高于R1切除组(100.0%vs.50.0%;P=0.025)。总之,这些结果表明,对于CLC患者实现治愈性切除是重要的,无论单个肿瘤中CLC成分的比例如何,CLC都可能具有良好的预后。
    Cholangiolocarcinoma (CLC) is an extremely rare tumor classified as a subtype of small duct-type intrahepatic cholangiocarcinoma (iCCA). There are few detailed reports on CLC and the prognostic impact of tumor heterogeneity is not clear. Between April 2006 and June 2022, of the 774 primary liver cancer resection cases who presented at Kanazawa University Hospital, 14 patients were pathologically diagnosed with CLC through immunohistochemical analysis of their molecular and biological features. Clinicopathological features and prognoses were evaluated retrospectively. Additionally, tumor heterogeneity was assessed and tumors were classified into pure and partial types according to the CLC component proportion in a single tumor. Chronic liver disease was observed in nine patients (64.3%). All tumors were mass-forming, and pathological R0 resection was achieved in 11 patients (78.6%). Tumor heterogeneity was classified as pure in 11 (78.6%) and partial in three (21.4%) patients. The median follow-up was 59.5 months (12-114 months). There was no difference in the 5-year disease-specific survival rates between the pure and partial (90.0% vs. 100.0%; P=0.200) types, but rates were significantly higher in the R0 resection group compared with those in the R1 resection group (100.0% vs. 50.0%; P=0.025). In conclusion, these results suggest that it is important for CLC patients to achieve curative resection, and CLC may have a good prognosis regardless of the proportion of CLC components in a single tumor.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    目的:在可切除的结直肠癌中,肿瘤部位与复发后病程和初次手术后预后的关系尚不清楚。这项研究调查了在I-III期结直肠癌中未经术前治疗的根治性切除术后原发肿瘤位置的预后影响。
    方法:我们分析了2000-15年间在我院接受根治性切除术的3770例I-III期结直肠癌患者。我们将右侧结肠定义为盲肠,升结肠和横结肠,左侧结肠作为降结肠,乙状结肠和直肠乙状结肠交界处。根据肿瘤部位将患者分为三组:右侧结肠,左侧结肠和直肠。终点是总生存期,分期无复发生存率和复发后生存率,分别。
    结果:I期左侧结肠癌患者的5年总生存率,右半结肠癌和直肠癌分别为98.2%、97.3%和97.2%,分别为(P=0.488)。II期左半结肠癌患者的5年总生存率,右半结肠癌和直肠癌分别为96.2,88.7和83.0(P=0.070).III期左半结肠癌患者的5年总生存率,右半结肠癌和直肠癌分别为88.7,83.0和80.2(P=0.001).I期左半结肠癌患者5年无复发生存率,右半结肠癌和直肠癌分别为95.1、94.5和90.6%(P=0.027)。II期左半结肠癌患者5年无复发生存率,右半结肠癌和直肠癌分别为85.2、90.2和76.1%,分别(P<0.001)。III期左半结肠癌患者的5年无复发生存率,右侧结肠癌和直肠癌分别为75.3、75.3和59.8%,分别(P<0.001)。校正临床因素后,与左侧结肠癌(HR1.29,95%CI1.03-1.63;P=0.025)和直肠癌(HR1.89,95%CI1.51-2.38;P<0.001)相比,右侧结肠癌具有更好的无复发生存率。在复发的患者中,与左侧结肠癌相比,右侧结肠癌与复发后的生存率显着相关(HR0.68,95%CI0.48-0.97;P=0.036),与直肠癌相比,复发后生存率下降(HR0.79,95%CI0.57-1.10;P=0.164)。
    结论:在未经术前治疗的I-III期结直肠癌中,我们的结果表明,三个肿瘤部位(右侧结肠,左侧结肠或直肠)可能对无复发生存率和复发后生存率具有预后意义,而不是单打独斗。
    OBJECTIVE: The relationship of tumour site with post-recurrence course and outcome after primary surgery in resectable colorectal cancer is unclear. This study investigated the prognostic impact of primary tumour location following radical resection without preoperative treatment in Stage I-III colorectal cancer.
    METHODS: We analyzed 3770 patients with Stage I-III colorectal cancer who underwent curative resection at our hospital during 2000-15. We defined the right-sided colon as the cecum, ascending colon and transverse colon, and the left-sided colon as the descending colon, sigmoid and rectosigmoid junction. Patients were divided into three groups according to tumour site: right-sided colon, left-sided colon and rectum. Endpoints were overall survival, recurrence-free survival by stage and survival after recurrence, respectively.
    RESULTS: The 5-year overall survival rates of patients with stage I left-sided colon cancer, right-sided colon cancer and rectal cancer were 98.2, 97.3 and 97.2%, respectively (P = 0.488). The 5-year overall survival rates of patients with Stage II left-sided colon cancer, right-sided colon cancer and rectal cancer were 96.2, 88.7 and 83.0, respectively (P = 0.070). The 5-year overall survival rates of patients with Stage III left-sided colon cancer, right-sided colon cancer and rectal cancer were 88.7, 83.0 and 80.2, respectively (P = 0.001). The 5-year recurrence-free survival rates of patients with Stage I left-sided colon cancer, right-sided colon cancer and rectal cancer were 95.1, 94.5 and 90.6% (P = 0.027). The 5-year recurrence-free survival rates of patients with Stage II left-sided colon cancer, right-sided colon cancer and rectal cancer were 85.2, 90.2 and 76.1%, respectively (P < 0.001). The 5-year recurrence-free survival rates of patients with Stage III left-sided colon cancer, right-sided colon cancer and rectal cancer were 75.3, 75.3 and 59.8%, respectively (P < 0.001). Right-sided colon cancer was significantly associated with better recurrence-free survival compared with left-sided colon cancer (HR 1.29, 95% CI 1.03-1.63; P = 0.025) and rectal cancer (HR 1.89, 95% CI 1.51-2.38; P < 0.001) after adjusting for clinical factors. Amongst patients with recurrence, right-sided colon cancer was significantly associated with poorer survival after recurrence compared with left-sided colon cancer (HR 0.68, 95% CI 0.48-0.97; P = 0.036), and showed a tendency towards poorer survival after recurrence compared with rectal cancer (HR 0.79, 95% CI 0.57-1.10; P = 0.164).
    CONCLUSIONS: In Stage I-III colorectal cancer without preoperative treatment, our results suggest that the three tumour sites (right-sided colon, left-sided colon or rectum) may have prognostic significance for recurrence-free survival and survival after recurrence, rather than sidedness alone.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    早期食管鳞状细胞癌的内镜治疗被广泛接受。内镜粘膜下剥离术(ESD),无论大小,都允许整块切除,提供切除的标本,有助于组织学评估的固化性。在组织学调查中,肿瘤深度的测定,淋巴血管受累,横向和纵向边缘在可固化性评估中起着重要作用。淋巴管浸润的诊断,特别是,通过添加免疫染色增强。ESD的长期结果与食管切除术相当,ESD因其并发症较少,可能成为早期食管癌的一线治疗方法.根治性切除后的监测也是必要的,因为食道癌的特点往往是现场癌变的概念,导致异时多发原发病变。
    Endoscopic treatment of early oesophageal squamous cell carcinoma is widely accepted. ESD (Endoscopic Submucosal Dissection), which allows en bloc resection regardless of size, provides resected specimens that facilitate histological evaluation of curability. In the histological investigation, the determination of tumor depth, lymphovascular involvement, and lateral and vertical margins play a great role in the assessment of curability. The diagnosis of lymphovascular invasion, in particular, is enhanced by the addition of immunostaining. The long-term outcome of ESD is comparable to that of oesophagectomy, and ESD may be the first-line treatment for early-stage oesophageal cancer due to its fewer complications. Surveillance after curative resection is also imperative because oesophageal cancer is often characterized by the concept of field cancerization, which results in metachronous multiple primary lesions.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

    求助全文

  • 文章类型: Journal Article
    背景:对于慢性乙型肝炎病毒(HBV)感染患者,越来越多的证据表明,扩大抗病毒治疗的适应症和适用人群的有效性。然而,肝细胞癌(HCC)抗病毒治疗的扩大适应症还有待进一步探讨.
    方法:在四川省人民医院接受根治性肝切除术和核苷(t)ide类似物(NAs)治疗的196例HBV相关HCC患者被纳入本研究。HCC复发,总生存期(OS),在不同的NAs治疗和使用抗程序性细胞死亡蛋白1(PD-1)治疗之间,比较了患者的早期病毒学(VR)和生化应答(BR).
    结果:NAs治疗在不同的手术时机是HBV相关HCC患者术后复发和总死亡率的一个强大的独立危险因素。此外,在接受术后抗PD-1治疗的HCC患者中,HBVDNA<1000拷贝/mL患者的无复发生存期(RFS)和OS显著优于HBVDNA≥1000拷贝/mL患者(HR:7.783;P=0.002;HR:6.699;P<0.001).然而,恩替卡韦组和富马酸替诺福韦酯组的RFS和OS率差异无统计学意义。在早期VR的比率中也观察到类似的结果,BR和组合VR和BR。
    结论:及时合理的术前NAs治疗在改善HBV相关HCC患者的预后方面具有临床益处。即使在正常的丙氨酸氨基转移酶(ALT)水平和e型肝炎抗原(HBeAg)阴性的情况下。此外,抗病毒治疗和抗PD-1治疗之间可能存在协同作用,需要进一步验证.
    BACKGROUND: For chronic hepatitis B virus (HBV) infection patients, increasing evidence has demonstrated the effectiveness of expanding the indications and applicable population for antiviral therapy. However, the expanded indication of antiviral therapy for hepatocellular carcinoma (HCC) remains to be further explored.
    METHODS: 196 HBV-related HCC patients who received radical hepatectomy and nucleos(t)ide analogues (NAs) therapy at Sichuan Provincial People\'s Hospital were enrolled in this study. HCC recurrence, overall survival (OS), early virological (VR) and biochemical responses (BR) of patients were compared between different NAs therapy and the use of anti-programmed cell death protein 1 (PD-1) therapy.
    RESULTS: NAs therapy at different timing of surgery was a strong independent risk factor for postoperative recurrence and overall mortality of HBV-related HCC patients. Furthermore, in HCC patients who received postoperative anti-PD-1 therapy, patients with HBV DNA < 1000 copy/mL had significantly better recurrence-free survival (RFS) and OS than those with HBV DNA ≥ 1000 copy/mL (HR: 7.783; P = 0.002; HR: 6.699; P < 0.001). However, the differences of RFS and OS rates between entecavir group and tenofovir disoproxil fumarate group were not statistically significant. Similar results were also observed in the rates of early VR, BR and combined VR and BR.
    CONCLUSIONS: Timely and reasonable preoperative NAs therapy showed clinical benefit in improving the prognosis of patients with HBV-related HCC, even in the case of normal alanine aminotransferase (ALT) level and negative hepatitis e antigen (HBeAg). Furthermore, a possible synergistic effect between antiviral therapy and anti-PD-1 therapy was founded and need further verification.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

  • 文章类型: Journal Article
    背景:老年癌症患者的数量有所增加,预计结直肠癌将受到这一趋势的影响。本研究旨在比较预后因素,包括营养和炎症指标,I-III期结直肠癌根治性切除术后年龄≥70岁和<70岁的患者之间的关系。
    方法:本研究纳入了560例I-III期结直肠癌患者,他们在2010年5月至2018年6月期间接受了根治性切除术。进行回顾性分析以确定年龄≥70岁和<70岁患者的预后相关变量。
    结果:术前体重指数低,高C反应蛋白/白蛋白比,合并疾病主要与≥70岁患者的不良预后有关。肿瘤因素与年龄<70岁患者的不良预后相关。在年龄≥70岁的人群中,C反应蛋白/白蛋白比值与不良的总生存率和无复发生存率独立相关。在大多数年龄≥70岁的患者的术后观察期间,C反应蛋白/白蛋白比的时间依赖性曲线下面积优于其他基于营养和炎症的指标。
    结论:肿瘤因素与年龄<70岁患者的不良预后相关。除了淋巴结转移,年龄≥70岁患者的术前状态与不良预后相关.具体来说,对于年龄≥70岁的I-III期结直肠癌患者,术前C反应蛋白/白蛋白比值与根治性切除术后的长期预后独立相关.
    BACKGROUND: The number of older patients with cancer has increased, and colorectal cancer is expected to be affected by this trend. This study aimed to compare prognostic factors, including nutritional and inflammation-based indices, between patients aged ≥ 70 and < 70 years following curative resection of stage I-III colorectal cancer.
    METHODS: This study included 560 patients with stage I-III colorectal cancer who underwent curative resection between May 2010 and June 2018. A retrospective analysis was performed to identify prognosis-associated variables in patients aged ≥ 70 and < 70 years.
    RESULTS: Preoperative low body mass index, high C-reactive protein/albumin ratio, and comorbidities were mainly associated with poor prognosis in patients aged ≥ 70 years. Tumor factors were associated with a poor prognosis in patients aged < 70 years. The C-reactive protein/albumin ratio was independently associated with poor overall survival and recurrence-free survival in those aged ≥ 70 years. The time-dependent area under the curve for the C-reactive protein/albumin ratio was superior to those of other nutritional and inflammation-based indices in most postoperative observation periods in patients aged ≥ 70 years.
    CONCLUSIONS: Tumor factors were associated with a poor prognosis in patients aged < 70 years. In addition to lymph node metastasis, preoperative statuses were associated with poor prognosis in patients aged ≥ 70 years. Specifically, the preoperative C-reactive protein/albumin ratio was independently associated with long-term prognosis in patients aged ≥ 70 years with stage I-III colorectal cancer after curative resection.
    导出

    更多引用

    收藏

    翻译标题摘要

    我要上传

       PDF(Pubmed)

公众号